Vincent Chung

10.3k total citations · 5 hit papers
169 papers, 3.6k citations indexed

About

Vincent Chung is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Vincent Chung has authored 169 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 123 papers in Oncology, 39 papers in Pulmonary and Respiratory Medicine and 38 papers in Cancer Research. Recurrent topics in Vincent Chung's work include Pancreatic and Hepatic Oncology Research (60 papers), Cancer Immunotherapy and Biomarkers (34 papers) and Cancer Genomics and Diagnostics (33 papers). Vincent Chung is often cited by papers focused on Pancreatic and Hepatic Oncology Research (60 papers), Cancer Immunotherapy and Biomarkers (34 papers) and Cancer Genomics and Diagnostics (33 papers). Vincent Chung collaborates with scholars based in United States, Australia and South Korea. Vincent Chung's co-authors include Idoroenyi Amanam, Daneng Li, Andrew Hendifar, Betty Ferrell, Michael J. Pishvaian, Subha Madhavan, Rohan Gupta, Jonathan R. Brody, Davendra Sohal and Lola Rahib and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Gastroenterology.

In The Last Decade

Vincent Chung

158 papers receiving 3.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial

2020 327 citations Michael J. Pishvaian, Edik M. Blais et al. profile →
A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer

2020 306 citations Vincent Chung, Daneng Li et al. profile →
Geriatric Assessment–Driven Intervention (GAIN) on Chemotherapy-Related Toxic Effects in Older Adults With Cancer

2021 236 citations Daneng Li, Can‐Lan Sun et al. profile →
First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆

2021 196 citations Vincent Chung et al. profile →
Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial

2024 124 citations Shubham Pant, Zev A. Wainberg et al. Nature Medicine profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Vincent Chung	2.3k	897	830	646	631	169	3.6k
Toon Van Gorp	1.1k 0.5×	743 0.8×	526 0.6×	1.3k 2.1×	389 0.6×	219	4.8k
B. Weber	1.6k 0.7×	686 0.8×	451 0.5×	824 1.3×	536 0.8×	97	3.8k
Petronella O. Witteveen	2.0k 0.9×	807 0.9×	436 0.5×	702 1.1×	799 1.3×	95	3.8k
Linda Duska	1.2k 0.5×	679 0.8×	332 0.4×	845 1.3×	575 0.9×	232	4.4k
Jean‐Philippe Spano	3.0k 1.3×	1.1k 1.3×	542 0.7×	448 0.7×	1.2k 1.9×	190	5.1k
Jean‐Paul Guastalla	2.2k 0.9×	621 0.7×	674 0.8×	521 0.8×	495 0.8×	109	3.7k
Angeles Alvarez Secord	2.3k 1.0×	1.5k 1.6×	675 0.8×	1.1k 1.7×	738 1.2×	288	7.2k
Kyung-Hun Lee	4.1k 1.8×	1.6k 1.8×	1.5k 1.9×	706 1.1×	2.0k 3.1×	216	6.0k
Paola A. Gehrig	1.7k 0.7×	1.7k 1.9×	788 0.9×	1.3k 2.0×	642 1.0×	221	7.5k
Abenaa M. Brewster	2.2k 0.9×	862 1.0×	1.5k 1.8×	294 0.5×	408 0.6×	114	3.8k

Countries citing papers authored by Vincent Chung

Since Specialization

Citations

This map shows the geographic impact of Vincent Chung's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vincent Chung with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vincent Chung more than expected).

Fields of papers citing papers by Vincent Chung

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vincent Chung. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vincent Chung. The network helps show where Vincent Chung may publish in the future.

Co-authorship network of co-authors of Vincent Chung

This figure shows the co-authorship network connecting the top 25 collaborators of Vincent Chung. A scholar is included among the top collaborators of Vincent Chung based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vincent Chung. Vincent Chung is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wainberg, Zev A., Colin D. Weekes, Muhammad Furqan, et al.. (2025). Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results. Nature Medicine. 31(11). 3648–3653. 7 indexed citations

Tsai, Frank, Michael J. Birrer, Jason R. Brown, et al.. (2024). A phase 2 clinical trial of first-in-class fascin inhibitor NP-G2-044 as monotherapy and in combination therapy with anti-PD-1 immunotherapy in patients with advanced solid tumor malignancies.. Journal of Clinical Oncology. 42(16_suppl). 3112–3112. 2 indexed citations

Devoe, Craig, Shubham Pant, Zev A. Wainberg, et al.. (2024). AMPLIFY-7P, a first-in-human safety and efficacy trial of adjuvant mKRAS-specific lymph node targeted amphiphile ELI-002 7P vaccine in patients with minimal residual disease–positive pancreatic and colorectal cancer.. Journal of Clinical Oncology. 42(16_suppl). 2636–2636. 9 indexed citations

Abi‐Jaoudeh, Nadine, David K. Imagawa, Zachary S. Sacks, et al.. (2024). Phase 1 study to evaluate safety and preliminary efficacy of padeliporfin vascular targeted photodynamic therapy (VTP) in patients with locally advanced (LA) unresectable pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology. 42(16_suppl). TPS4204–TPS4204. 1 indexed citations

Pant, Shubham, Zev A. Wainberg, Colin D. Weekes, et al.. (2024). Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial. Nature Medicine. 30(2). 531–542. 124 indexed citations breakdown →

Chung, Vincent, et al.. (2024). Neoadjuvant treatment for pancreatic cancer: Controversies and advances. Cancer Treatment and Research Communications. 39. 100804–100804. 3 indexed citations

Soto‐Pérez‐de‐Celis, Enrique, William Dale, Vani Katheria, et al.. (2024). Outcome prioritization and preferences among older adults with cancer starting chemotherapy in a randomized clinical trial. Cancer. 130(17). 3000–3010. 13 indexed citations

Barzi, Afsaneh, Howard West, David T. Wong, et al.. (2023). Pancreatic Adenocarcinoma: Real World Evidence of Care Delivery in AccessHope Data. Journal of Personalized Medicine. 13(9). 1377–1377. 1 indexed citations

Villalona‐Calero, Miguel A., Jyoti Malhotra, Vincent Chung, et al.. (2023). Integrating Early-Stage Drug Development with Clinical Networks; Challenges and Opportunities: The City of Hope Developing Experience. Journal of Clinical Medicine. 12(12). 4061–4061.

10.

Liu, Jason, Heather M. McGee, Vincent Chung, et al.. (2022). Advances in Radiation Oncology for Pancreatic Cancer: An Updated Review. Cancers. 14(23). 5725–5725. 6 indexed citations

11.

Thornblade, Lucas W., Paul Wong, Daneng Li, et al.. (2021). Patterns of Whole Exome Sequencing in Resected Cholangiocarcinoma. Cancers. 13(16). 4062–4062. 7 indexed citations

12.

Ferrell, Betty, Vincent Chung, Mark T. Hughes, et al.. (2020). A Palliative Care Intervention for Patients on Phase 1 Studies. Journal of Palliative Medicine. 24(6). 846–856. 29 indexed citations

13.

Hardwick, Nicola, Paul Frankel, Christopher Ruel, et al.. (2018). p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy. Clinical Cancer Research. 24(6). 1315–1325. 54 indexed citations

14.

Pishvaian, Michael J., R Joseph Bender, Lola Rahib, et al.. (2018). Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative. Clinical Cancer Research. 24(20). 5018–5027. 149 indexed citations

15.

Amanam, Idoroenyi & Vincent Chung. (2018). Targeted Therapies for Pancreatic Cancer. Cancers. 10(2). 36–36. 61 indexed citations

16.

Ferrell, Betty, et al.. (2017). Characteristics of Participants Enrolled onto a Randomized Controlled Trial of Palliative Care for Patients on Phase I Studies. Journal of Palliative Medicine. 20(12). 1338–1344. 18 indexed citations

17.

Gupta, Rohan, Idoroenyi Amanam, & Vincent Chung. (2017). Current and future therapies for advanced pancreatic cancer. Journal of Surgical Oncology. 116(1). 25–34. 123 indexed citations

18.

Hurria, Arti, Chie Akiba, Jérôme H. Kim, et al.. (2016). Reliability, Validity, and Feasibility of a Computer-Based Geriatric Assessment for Older Adults With Cancer. Journal of Oncology Practice. 12(12). e1025–e1034. 65 indexed citations

19.

Manuel, Edwin R., Massimo D’Apuzzo, Teodora Kaltcheva, et al.. (2015). Salmonella -Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors. Cancer Immunology Research. 3(9). 1096–1107. 53 indexed citations

20.

Hardwick, Nicola, Mary Carroll, Teodora Kaltcheva, et al.. (2014). p53MVA Therapy in Patients with Refractory Gastrointestinal Malignancies Elevates p53-Specific CD8+ T-cell Responses. Clinical Cancer Research. 20(17). 4459–4470. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact